Get the Stockscreener App
3.86
4.69%
-0.19
After Hours:
4.05
0.19
+4.92%
Exagen Inc stock is traded at $3.86, with a volume of 138.90K.
It is down -4.69% in the last 24 hours and up +11.88% over the past month.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
See More
Previous Close:
$4.05
Open:
$4.05
24h Volume:
138.90K
Relative Volume:
0.96
Market Cap:
$72.49M
Revenue:
$52.55M
Net Income/Loss:
$-23.69M
P/E Ratio:
-4.1064
EPS:
-0.94
Net Cash Flow:
$-15.29M
1W Performance:
+6.63%
1M Performance:
+11.88%
6M Performance:
+29.53%
1Y Performance:
+171.83%
1-Day Range:
$3.71
$4.06
1-Week Range:
$3.41
$4.19
52-Week Range:
$1.3003
$6.22
Exagen Inc Stock (XGN) Company Profile
Name
Exagen Inc
Sector
Industry
Phone
(760) 560-1501
Address
1261 LIBERTY WAY, VISTA, CA
Compare XGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XGN
Exagen Inc
|
3.86 | 72.49M | 52.55M | -23.69M | -15.29M | -0.94 |
|
TMO
Thermo Fisher Scientific Inc
|
514.34 | 196.14B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
212.40 | 152.09B | 23.88B | 3.90B | 5.30B | 5.28 |
|
IDXX
Idexx Laboratories Inc
|
417.66 | 34.45B | 3.90B | 887.87M | 798.08M | 10.67 |
|
A
Agilent Technologies Inc
|
120.51 | 34.37B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
181.39 | 32.81B | 15.41B | 1.37B | 2.11B | 7.50 |
Exagen Inc Stock (XGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-05-22 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Apr-15-21 | Initiated | Canaccord Genuity | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Oct-08-20 | Initiated | BTIG Research | Buy |
| Jun-02-20 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-14-19 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-14-19 | Initiated | Cowen | Outperform |
| Oct-14-19 | Initiated | William Blair | Outperform |
View All
Exagen Inc Stock (XGN) Latest News
Exagen Inc. (XGN) Reports Q4 Loss, Tops Revenue Estimates - MSN
FY2025 EPS Estimates for Exagen Lowered by Cantor Fitzgerald - Defense World
Equities Analysts Offer Predictions for Exagen Q1 Earnings - Defense World
Exagen Inc. (NASDAQ:XGN) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock? - Yahoo Finance
William Blair Reaffirms “Outperform” Rating for Exagen (NASDAQ:XGN) - Defense World
FY2026 Earnings Forecast for Exagen Issued By William Blair - Defense World
FY2024 EPS Estimates for Exagen Raised by Cantor Fitzgerald - Defense World
Exagen Inc. Reports Record Revenue and Positive Outlook - TipRanks
Exagen Inc. (NASDAQ:XGN) Q4 2024 Earnings Call Transcript - Insider Monkey
Exagen Full Year 2024 Earnings: EPS Beats Expectations - Yahoo Finance
Exagen’s Positive Outlook: Buy Rating Backed by Strong Performance and Growth Potential - TipRanks
Exagen Inc (XGN) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic Growth Initiatives - Yahoo Finance
Exagen Inc. Reports Record 2024 Financial Results - TipRanks
BTIG maintains Buy rating, $5 target on Exagen stock - Investing.com
BTIG maintains Buy rating, $5 target on Exagen stock By Investing.com - Investing.com Australia
Earnings call transcript: Exagen Inc Q4 2024 sees revenue growth and stock rise - Investing.com
Exagen posts smaller-than-expected fourth-quarter net loss -March 11, 2025 at 09:39 am EDT - Marketscreener.com
Exagen Inc reports results for the quarter ended December 31Earnings Summary - TradingView
EXAGEN INC. SEC 10-K Report - TradingView
EXAGEN DIAGNOSTICS Earnings Results: $XGN Reports Quarterly Earnings - Nasdaq
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business Highlights - The Manila Times
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results - TradingView
EXAGEN DIAGNOSTICS Earnings Preview: Recent $XGN Insider Trading, Hedge Fund Activity, and More - Nasdaq
Exagen (XGN) Expected to Announce Earnings on Tuesday - Defense World
Exagen Inc. (NASDAQ:XGN) Short Interest Update - Defense World
Is Exagen (NASDAQ:XGN) Using Debt In A Risky Way? - Simply Wall St
Investors in Exagen (NASDAQ:XGN) have unfortunately lost 84% over the last five years - Yahoo Finance
Exagen Inc. to Announce Fourth Quarter and Full-Year 2024 Financial Results on March 11, 2025 - GlobeNewswire
When Will Exagen Report Q4 Earnings? Key Date for Autoimmune Testing Investors - StockTitan
Stocks Surge Across Health Services and Industry Sectors: Nuvve, Exagen, and Flexsteel Lead the Way - HPBL
What Do Wall Street Analysts Think About Exagen Inc (NASDAQ: XGN) Stock? - Stocks Register
Exagen Inc. (NASDAQ:XGN) Short Interest Up 260.8% in January - MarketBeat
Exagen Inc Stock (XGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Exagen Inc Stock (XGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Black Jeffrey G. | Chief Financial Officer |
Nov 15 '24 |
Buy |
2.98 |
22,298 |
66,448 |
274,492 |
| ABALLI JOHN | President and CEO |
Nov 14 '24 |
Buy |
2.81 |
24,305 |
68,297 |
689,799 |
1.00%
0.49%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):